FAME 3 Cost-Effectiveness| JACC | TCT 2025

JACC is pleased to bring readers several studies and presentations for TCT 2025 this year. In this interview, JACC Senior Advisor. David J. Cohen, MD and Mark A. Hlatky, MD, discuss the cost-effectiveness analysis conducted alongside the FAME 3 trial, comparing PCI guided by fractional flow reserve with CABG. They conclude that while both procedures yield similar long-term clinical outcomes, PCI is significantly less expensive—making it the economically favorable option for patients with equipoise in treatment choice.